Estratest Shortage: What Providers and Prescribers Need to Know in 2026

Providers prescribing Estratest (esterified estrogens/methyltestosterone) are increasingly fielding calls and portal messages from patients who cannot fill their prescriptions. While EEMT is not currently listed on the FDA's official drug shortage database, persistent localized supply gaps continue to affect patients across the country in 2026.

This article provides a clinical overview of the factors driving EEMT unavailability, the regulatory landscape, and evidence-based guidance for managing affected patients — including alternatives, prior authorization considerations, and resources for helping patients locate their medication.

What Is Estratest and Who Is It Prescribed For?

Estratest (esterified estrogens/methyltestosterone) is a combination oral hormone therapy that pairs esterified estrogens with low-dose methyltestosterone, a synthetic androgen. It is indicated for the treatment of moderate to severe vasomotor symptoms of menopause in patients who have not achieved adequate relief from estrogen-only therapy.

It is available in two strengths:

Full strength (EEMT DS): 1.25 mg esterified estrogens / 2.5 mg methyltestosterone

Half strength (EEMT HS): 0.625 mg esterified estrogens / 1.25 mg methyltestosterone

The standard prescribing regimen is cyclic: typically one tablet daily for 3 weeks on and 1 week off. Off-label uses include adjunctive treatment of hypoactive sexual desire disorder (HSDD) and menopausal mood and fatigue symptoms unresponsive to estrogen monotherapy.

Regulatory and Approval Status: What Providers Should Know

EEMT has a complex regulatory history that affects both its availability and its formulary standing:

Not FDA-approved via NDA: EEMT was first marketed in 1964 — prior to the formal NDA approval pathway — and has never received modern FDA approval. It remains legally marketed under older regulatory provisions.

FDA efficacy questions: The FDA has previously noted it does not believe there is substantial evidence that the androgen component contributes to the effectiveness of the combination for vasomotor symptoms. This has informed some prescribers' risk-benefit assessments.

DEA Schedule III / Exemption status: Methyltestosterone is classified as a Schedule III controlled substance under the Anabolic Steroids Act of 1990. However, the DEA designated several specific EEMT combination products as exempt anabolic steroid products in June 2020, reducing the regulatory burden for those particular formulations.

Prescribing rules: For non-exempt formulations, prescriptions may require a handwritten or electronic Schedule III prescription, and refills may be limited by state law. For exempt formulations, standard prescription rules apply. Verify with your state's pharmacy board.

Why Is EEMT Hard to Find? A Supply Chain Analysis

The supply chain vulnerabilities for EEMT stem from several structural factors:

Limited generic manufacturer base: After Solvay discontinued the Estratest brand in March 2009, generic manufacturers absorbed the market. However, only a small number actively produce the drug. Any manufacturing disruption — quality issues, raw material supply, or business decisions — affects the entire market with minimal backup capacity.

Niche market economics: EEMT is a second-line menopause therapy by indication. The eligible patient population — postmenopausal women who didn't respond to estrogen monotherapy — is smaller than the overall HRT market, reducing manufacturer incentives to maintain high production capacity.

Regulatory compliance overhead: Even for exempt formulations, production requires compliance with both FDA pharmaceutical manufacturing regulations and DEA production quotas (for non-exempt products). This compliance burden raises costs for smaller manufacturers.

Clinical Guidance: Managing Patients Who Cannot Fill EEMT

When a patient cannot fill their EEMT prescription, providers have several pathways:

Option A: Help the Patient Find the Medication

Before initiating a therapeutic substitution, consider whether the patient has exhausted all local pharmacy options. Directing patients to medfinder for providers can help — the service calls pharmacies to locate in-stock medications so patients don't have to. Specify both strength variants and all generic names.

Option B: Prescribe a Compounded Formulation

If commercial EEMT is genuinely unavailable in the patient's area, a compounding pharmacy can prepare the same combination — esterified estrogens/methyltestosterone — using a compounding prescription. Note that compounded hormones are not subject to FDA approval requirements. Discuss the implications of using a compounded product with the patient, including potential variability in potency and the absence of manufacturer safety data.

Option C: Therapeutic Substitution with Evidence-Based Alternatives

If the patient's symptoms can be managed without the androgen component, standard estrogen-based HRT is an appropriate alternative. Key considerations:

Estradiol (various formulations): Oral, transdermal patch, gel, or spray; FDA-approved; widely available. Add progestogen if uterus intact.

Premarin (conjugated estrogens): Oral tablet; FDA-approved; robust long-term safety data from the WHI and prior studies. Add progestogen if uterus intact.

Prempro (conjugated estrogens/medroxyprogesterone): Combination pill; appropriate for patients with intact uterus who need combined estrogen-progestin therapy.

Bijuva (estradiol/progesterone): FDA-approved bioidentical combination; appropriate for patients with a uterus who prefer progesterone over synthetic progestins.

If HSDD or fatigue were primary indications for the methyltestosterone component, consider separate evaluation for low testosterone in postmenopausal women (off-label testosterone therapy), or referral to a menopause specialist (NAMS-certified provider).

Prior Authorization and Formulary Considerations

Because EEMT has not been approved through the modern NDA process, some payers treat it as an unapproved drug and may not cover it, or may require step therapy through FDA-approved estrogen products first. When appealing prior authorization denials, emphasize:

Documentation of failed estrogen-only trials (required by indication)

The unique androgen component and its clinical rationale for this patient

That EEMT has been continuously marketed for over 60 years under established regulatory provisions

Summary for Clinical Practice

EEMT's ongoing availability challenges are structural rather than temporary. Providers should anticipate that patients will periodically report inability to fill their prescription, and proactive communication about alternatives reduces crisis-mode care. Directing patients to medfinder.com/providers before the prescription lapses can prevent unnecessary gaps in treatment and reduce provider and staff workload from reactive calls.